Generating new and novel biologics

JJP Biologics is an innovative biotechnology company developing the next generation of novel biologics in the field of personalized medicine.

We are part of the growing Polish biotechnology sector, led by some of the biggest names in the industry and backed by the Starak family.

Who we are

We are scientists, researchers, investors and development specialists located across Europe. We come up with new approaches for addressing today and tomorrow’s health issues—focusing on personalized medicines. We develop our innovative biologics for a personalized medicine strategy for which companion diagnostics are
available leveraging our core R&D expertise to advance science. 

We don’t just focus on treating illness, but also improving quality of life and improving society and scientific understanding.

Part of Polish Biotechnology

Over the last decade a new a biotechnology sector has been created almost from scratch in Poland. Through consistent investment, not only in laboratories and production lines, but also in know-how, it has driven the growth of highly-qualified jobs, as well as developed cooperation between science and business.

JJP Biologics is a new member to this growing biotechnology sector, led by specialists drawn from leading global pharmaceutical companies. We have invested significantly in supporting research and development carried out in Poland and contribute through collaborations with universities, pharmaceutical companies, industries and other drug developers.

JJP Biologics closely cooperates with research centres and universities across Poland to advance innovative research. At JJP Biologics, we are one of the few companies developing truly innovative biologics, that will advance science and improve patient outcomes.



To ensure our efforts have the biggest impact we collaborate with peers, academics, clinical experts, front-line health professionals, governments and advocacy groups. This focuses our efforts on the things that truly make a difference to patient outcomes and experience.


Research and innovation is the bedrock of our business. We advance leading-edge science through a dynamic and collaborative approach. This enables us to find better solutions for treating the world’s most challenging diseases. We focus on discovering, developing and delivering drugs in therapeutic areas where we have proven expertise—and can make an impact. This is mainly focused around immunology, inflammation and oncology.

Our Pipeline & Portfolio

We develop innovative biologics for which companion diagnostics are available to enable a personalized medicine strategy.

Companion diagnostics are diagnostic tests used to check whether a therapeutic drug will be applicable and effective in a specific patient. These diagnostics detect the presence of a biomarker, that is associated with disease severity and related to the disease pathology.

We aim to progress our programs to proof-of-concept studies in the clinic. If you are interested in our programs please contact us.



At JJP Biologics, our commitment to excellence begins at the top. With decades of combined experience in the development, manufacture and commercialization of biopharmaceuticals, a solid foundation is provided for novel therapeutic approaches. Our international management team brings both knowledge and passion to every program.

Dr Louis Boon - CSO, Management Board Member

Louis is the CSO and Management Board Member of JJP Biologics. Louis obtained his Ph.D. in Biochemistry at the University of Amsterdam. He was founder of various companies focused around the generation and development therapeutic monoclonal antibodies, primarily in the field of cancer and inflammation. In 2003, he was one of the founders of Bioceros BV, now Polpharma Biologics, where he currently holds the position of Principle Scientific Advisor. In addition, he held positions as CSO for MacroZyme BV, 4AZA Bioscience NV, FF Pharma and VP preclinical for PanGenetics BV and Tanox. Louis is an author of over 325 publications in international scientific journals in the field of medical biotechnology and an inventor at more than 20 patent applications.

Pawel Szczepanski - COO, Management Board Member

Paweł is the COO and Management Board Member of JJP Biologics. Involved in the biopharmaceutical market since 2014 as Supervisory Board Member of Polpharma Biologics Warsaw. Paweł has built experience in the pharmaceutical industry since 2010. First in a pharma-specialized advisory and market research house and subsequently in various capacities in Polpharma, including Director of Corporate Project Office. Prior to that has worked for six years in investment banking and management consulting in Portugal and Poland. Paweł also serves as a Supervisory Board member of Herbapol Lublin. Paweł graduated from the Warsaw School of Economics (MSc) and holds a master’s degree in law from the Warsaw University.

Scientific Advisory Board

Our advisory board brings immense expertise with international experience in the development of novel biologics.

Dr Joerg Windisch

Dr Joerg Windisch has around 25 years of experience in the development, manufacture and regulatory licensure of biologic therapies. He is currently Vice Chairman of Supervisory Board Polpharma Biologics Group, Dr Windisch has made significant contributions to the organization’s formation and growth, and the development of its frontrunner products. Prior to joining Polpharma, Dr Windisch served as the Chief Operating Officer (COO) for Affimed, a NASDAQ-traded biotech company which develops innovative bi- and trispecific antibodies as immune cell engagers to treat various kinds of cancer. Before that, Dr Windisch spent almost 20 years at Novartis/Sandoz where he most recently served as ChieCSO for Sandoz Biopharmaceuticals. He was a key figure in developing the first biosimilars approved in Europe and the US.

Prof. Marjolein van Egmond

Marjolein is currently Professor Oncology and Inflammation at Amsterdam UMC, location VU University Medical Center (VUmc). Her laboratory studies antibody activation of innate myeloid immune cells, macrophages and neutrophils, with emphasis on understanding the role of immunoglobulin A (IgA) in physiology and pathology. Her groups research focuses specifically on (1) the contribution of abnormal antibody responses to chronic inflammation and autoimmunity – (2) monoclonal antibody therapy of cancer. Dr. van Egmond’s research is highly translational and she is cross appointment with the Department of Surgery and the Department of Molecular Cell Biology and Immunology, to facilitate the rapid progression of pre-clinical findings into clinical applications.

Prof. Wiesław W. Jędrzejczak

MD is the head of the Department of Hematology, Transplantology and Internal Medicine at the Medical University of Warsaw. He is the Chairman of the Committee for Immunology and Etiology of Human Infections at the Polish Academy of Sciences. He specializes in internal diseases, hematology, clinical oncology and transplantology. For many years, Prof. Jędrzejczak was a national consultant in the field of hematology. His professional and scientific career is mainly connected to research related to hematopoietic stem cells and cytokines.

Prof. Jędrzejczak is one of the pioneers of chemotherapy in Poland.He discovered the first disease entity known in the medical world caused by a congenital lack of a cytokine (Macrophage Colony Stimulating Factor). As early as 1984, he and his team performed the first allogeneic marrow transplant in Poland. A year later, he carried out the first autologous transplant. Since then, he has performed over 1,000 such procedures. Prof. Jędrzejczak remains the undisputed authority in the field of clinical research regarding new drugs for the treatment of blood diseases. He has authored over 300 publications in renowned scientific journals.


Want to Stay Informed?
Get Our Latest Updates

Subscribe to receive our regular updates